Aloe Therapeutics

Aloe Therapeutics is a private, preclinical-stage biotech based in San Diego, founded in 2018, focused on overcoming resistance to checkpoint inhibitors in solid tumors. Its core technology, AIM-001, is an off-the-shelf, non-engineered cell therapy delivered locally to bait a potent, systemic immune response by mimicking transplant rejection biology. The company aims to improve response rates and durability for the majority of solid tumor patients who do not benefit from current immunotherapies, with a product designed for ease of integration into standard surgical and biopsy procedures.

Allo-IMMUNOTHERAPY platform harnessing transplant rejection biology. Utilizes off-the-shelf, non-engineered allogeneic cells delivered locally to tumor sites to bait a potent, systemic immune response and sensitize tumors to checkpoint inhibitors.

Competes in the crowded field of therapies aiming to convert immunologically 'cold' tumors to 'hot.' Competitors include developers of oncolytic viruses (e.g., Amgen's Imlygic), intratumoral cytokines, STING agonists, and other novel immunomodulators. Differentiation hinges on demonstrating superior potency from the transplant rejection mechanism and a favorable safety and convenience profile.